![](https://cdn.sanity.io/images/0vv8moc6/onclive/804cbe411f2f08408aa3638c71f815f3b9a4beab-200x200.jpg?fit=crop&auto=format)
KIM-1 Demonstrates Potential Utility as a Biomarker With Worse DFS Outcomes in KIM-1–High RCC
With the presentation of an exploratory analysis of KIM-1 biomarker data from the phase 3 IMmotion010 trial (NCT03024996) at the 2024 ASCO Annual Meeting, a third prospective trial has shown that higher KIM-1 levels at baseline result in worse disease-free …